Compugen to Participate in Stifel 2024 Healthcare Conference

Core Insights - Compugen Ltd. is a clinical-stage cancer immunotherapy company that will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 18, 2024 [1] - The event will be accessible via a live webcast on the company's Investor Relations website, with a replay available afterward [2] Company Overview - Compugen utilizes its predictive computational discovery platform, UnigenTM, to identify new drug targets and biological pathways for cancer immunotherapies [3] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [3] - Rilvegostomig, a PD-1/TIGIT bispecific antibody, is in Phase 3 development by AstraZeneca under a licensing agreement [3] - Compugen's pipeline includes early-stage immuno-oncology programs, with COM503, an anti-IL-18 binding protein antibody, having received IND clearance from the FDA and licensed to Gilead [3] - Compugen is headquartered in Israel and has offices in San Francisco, CA, with shares listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [3]